Literature DB >> 12544695

Abnormal levels of neuropeptide Y and peptide YY in the colon in irritable bowel syndrome.

Magnus Simrén1, Per-Ove Stotzer, Henrik Sjövall, Hasse Abrahamsson, Einar S Björnsson.   

Abstract

OBJECTIVE: To assess the levels of gut peptides involved in gastrointestinal motor, secretory and sensory function in colonic biopsies in irritable bowel syndrome (IBS) patients and healthy controls.
METHODS: We studied 34 patients with IBS and 15 subjects without gastrointestinal symptoms. The predominant bowel pattern in the IBS patients was constipation in 17 patients (IBS-C) and diarrhoea in 17 patients (IBS-D). With radioimmunoassay, the levels of vasoactive intestinal peptide (VIP), substance P, neuropeptide Y (NPY) and peptide YY (PYY) were analysed in biopsies from the descending colon and ascending colon obtained during colonoscopy.
RESULTS: The IBS patients had lower levels of PYY in the descending colon than the controls, but the levels in the ascending colon did not differ. The NPY levels were lower in IBS-D than in IBS-C, both in the ascending colon and in the descending colon. Low levels of VIP were more common in IBS patients, but mean levels did not differ between groups. No group differences were observed for substance P. The levels of VIP, substance P and NPY were higher in the ascending colon than in the descending colon, whereas the opposite pattern was seen for PYY.
CONCLUSION: IBS patients demonstrate lower levels of PYY in the descending colon than controls. Colonic NPY levels differ between IBS subgroups based on the predominant bowel pattern. These findings may reflect the pathophysiology of IBS and the symptom variation within the IBS population. Copyright 2003 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12544695     DOI: 10.1097/00042737-200301000-00010

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  10 in total

Review 1.  Inflammation in irritable bowel syndrome: Myth or new treatment target?

Authors:  Emanuele Sinagra; Giancarlo Pompei; Giovanni Tomasello; Francesco Cappello; Gaetano Cristian Morreale; Georgios Amvrosiadis; Francesca Rossi; Attilio Ignazio Lo Monte; Aroldo Gabriele Rizzo; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 2.  Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders-an alternative model for pathogenesis: cytokine controlled transepithelial multi-feedback loop.

Authors:  Ricky McCullough; Jeremiah McCullough
Journal:  Transl Gastroenterol Hepatol       Date:  2017-03-17

3.  A role for endogenous peptide YY in tachykinin NK(2) receptor-triggered 5-HT release from guinea pig isolated colonic mucosa.

Authors:  Shu-ichi Kojima; Atsushi Tohei; Naohiko Anzai
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

4.  Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome.

Authors:  Olafur S Palsson; Olivier Morteau; Eugene M Bozymski; John T Woosley; R Balfour Sartor; Michael J Davies; David A Johnson; Marsha J Turner; William E Whitehead
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

5.  Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress.

Authors:  I Posserud; P Agerforz; R Ekman; E S Björnsson; H Abrahamsson; M Simrén
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

6.  Rectal hypersensitivity reduced by acupoint TENS in patients with diarrhea-predominant irritable bowel syndrome: a pilot study.

Authors:  Wen-Bin Xiao; Yu-Lan Liu
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

Review 7.  Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome.

Authors:  Maria M Buckley; Siobhain M O'Mahony; Dervla O'Malley
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

8.  Symptom pattern following a meal challenge test in patients with irritable bowel syndrome and healthy controls.

Authors:  Iris Posserud; Hans Strid; Stine Störsrud; Hans Törnblom; Ulla Svensson; Jan Tack; Lukas Van Oudenhove; Magnus Simrén
Journal:  United European Gastroenterol J       Date:  2013-10       Impact factor: 4.623

Review 9.  Potential neuro-immune therapeutic targets in irritable bowel syndrome.

Authors:  Maite Casado-Bedmar; Åsa V Keita
Journal:  Therap Adv Gastroenterol       Date:  2020-04-09       Impact factor: 4.409

10.  Human colon-derived soluble factors modulate gut microbiota composition.

Authors:  Arancha Hevia; David Bernardo; Enrique Montalvillo; Hafid O Al-Hassi; Luis Fernández-Salazar; Jose A Garrote; Christian Milani; Marco Ventura; Eduardo Arranz; Stella C Knight; Abelardo Margolles; Borja Sánchez
Journal:  Front Oncol       Date:  2015-04-13       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.